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Stroke is the leading cause of disability and is the third leading 
cause of death in women in the United States. Of the 500,000 
patients affected by a new stroke, nearly 200,000 will affect 
women. 1 In addition, approximately 90,000 American women 
die each year from a stroke, accounting for 60% of all stroke 
deaths. 1 The mortality rate from stroke is higher in women; the 
death rate from stroke is 16%, while it is 8% in men.2 The reason 
for the higher death rate is the older age of women at the time of 
their initial stroke. The impact of stroke in women extends 
beyond the individual, since women are often the primary care 
giver to children and are often responsible for the care of an aged 
or ill spouse. 
There are various risk factors that have been identified for 
stroke; however, except for some unique situations such as 
pregnancy and the use of oral contraceptives, the risk factors for 
stroke appear to be the same for men and women. In the last few 
decades, there has been a decline in the mortality rate from 
stroke, primarily because of better control of risk factors such as 
hypertension. However, the rate of the decline has slowed both 
in men and women. 
Hypertension is the leading risk factor for stroke in both men 
and women. The prevalence of hypertension as a risk factor is 
two times higher in Afro-American women as compared to 
Caucasian women. 3 Treatment of hypertension, including iso-
lated systolic elevations, effectively reduces the risk of stroke.4 
Cigarette smoking is another treatable risk factor for stroke-
smoking is a major risk factor for the development of carotid 
atherosclerosis. Women cigarette smokers have a three-fold 
increase in the risk of stroke compared to nonsmokers. The risk 
of stroke increases with the number of cigarettes smoked.5 The 
risk of stroke can be reduced by smoking cessation.5 
After hypertension, heart disease is the most important risk 
factor for stroke. Cardiac disease accounts for approximately 
20% of strokes. Atrial fibrillation is more common in men in all 
age groups6; however, after age 80, the incidence in women 
approaches that of men. 6 The Stroke Prevention in Atrial Fibril-
lation (SPAF) study has suggested that in patients less than 75 
years of age with no risk factors of congestive heart failure, 
hypertension or prior thromboembolism aspirin can be recom-
mended.7 Those less than 75 years with risk factors should be 
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treated with long-term, low-dose warfarin therapy. Patients over 
age 75 years present a dilemma because the protection is not 
great with either aspirin or warfarin. The SP AF m study is in 
progress to further study this question. 
Mitral valve prolapse is twice as common in women as in 
men8; however, women do not seem to be more prone than men 
to have a stroke with this condition.9 
Oral contraceptives with a higher dose of estrogen have been 
associated with a 9-times greater incidence of stroke.10 Women 
who are over age 35 and are hypertensive or are smokers have 
the greatest risk of having complications. The lower-dose estro-
gen preparations effect a lower risk of stroke.11 Postmenopausal 
use of conjugated estrogens appears to reduce the risk of 
vascular disease. 12 
Pregnancy increases the risk of stroke by 3 to 13 times. 13 Some 
potential etiologies include hypertension, cardiac lesions, in-
cluding peripartal cardiomyopathy, diabetes, hypercoagulabil-
ity, or amniotic, fat or air emboli. 
Fibromuscular dysplasia (FMD), an uncommon non-athero-
sclerotic vasculopathy, is more common in women. In one 
series, 95% of the persons affected with FMD were women.14 
Therapy for stroke prevention includes aspirin, ticlopidine, or 
warfarin. Risk factor modification of the treatable causes of 
stroke is important. In stroke in women, special attention often 
needs to be paid to assessing the support systems for care of 
children, a dependent spouse, and for household responsibili-
ties. 
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Surgery may be a last resort for severely affected patients 
unresponsive to other strategies. Total hysterectomy with bilat-
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PMS.29 
Although the etiology of PMS remains unclear there are 
strategies a clinician can utilize to alleviate symptoms. The 
problem is an important one and deserves our continued clinical 
attention and study. 
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